PPARs in Lung Biology and DiseaseView this Special Issue
Review Article | Open Access
Peroxisome Proliferator-Activated Receptors and Acute Lung Injury
Peroxisome proliferator-activated receptors are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. PPARs regulate several metabolic pathways by binding to sequence-specific PPAR response elements in the promoter region of target genes, including lipid biosynthesis and glucose metabolism. Recently, PPARs and their respective ligands have been implicated as regulators of cellular inflammatory and immune responses. These molecules are thought to exert anti-inflammatory effects by negatively regulating the expression of proinflammatory genes. Several studies have demonstrated that PPAR ligands possess anti-inflammatory properties and that these properties may prove helpful in the treatment of inflammatory diseases of the lung. This review will outline the anti-inflammatory effects of PPARs and PPAR ligands and discuss their potential therapeutic effects in animal models of inflammatory lung disease.
- R. Hess, W. Stäubli, and W. Riess, “Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat,” Nature, vol. 208, no. 13, pp. 856–858, 1965.
- J. Vamecq and N. Latruffe, “Medical significance of peroxisome proliferator-activated receptors,” The Lancet, vol. 354, no. 9173, pp. 141–148, 1999.
- J. C. Corton, S. P. Anderson, and A. Stauber, “Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators,” Annual Review of Pharmacology and Toxicology, vol. 40, pp. 491–518, 2000.
- P. Dowell, J. E. Ishmael, D. Avram, V. J. Peterson, D. J. Nevrivy, and M. Leid, “Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor interacting protein,” Journal of Biological Chemistry, vol. 274, no. 22, pp. 15901–15907, 1999.
- J. C. Fruchart, B. Staels, and P. Duriez, “The role of fibric acids in atherosclerosis,” Current Atherosclerosis Reports, vol. 3, no. 1, pp. 83–92, 2001.
- B. Desvergne, L. Michalik, and W. Wahli, “Be fit or be sick: peroxisome proliferator-activated receptors are down the road,” Molecular Endocrinology, vol. 18, no. 6, pp. 1321–1332, 2004.
- A. Fredenrich and P. A. Grimaldi, “PPAR delta: an uncompletely known nuclear receptor,” Diabetes and Metabolism, vol. 31, no. 1, pp. 23–27, 2005.
- A. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, “The role of peroxisome proliferator-activated receptor- in epithelial cell growth and differentiation,” Cellular Signalling, vol. 18, no. 1, pp. 9–20, 2006.
- C. A. Argmann, T.-A. Cock, and J. Auwerx, “Peroxisome proliferator-activated receptor : the more the merrier?,” European Journal of Clinical Investigation, vol. 35, no. 2, pp. 82–92, 2005.
- M. A. Lazar, “PPAR, 10 years later,” Biochimie, vol. 87, no. 1, pp. 9–13, 2005.
- H. Sundvold, A. Brzozowska, and S. Lien, “Characterisation of bovine peroxisome proliferator-activated receptors 1 and 2: genetic mapping and differential expression of the two isoforms,” Biochemical and Biophysical Research Communications, vol. 239, no. 3, pp. 857–861, 1997.
- S. Ueki, Y. Matsuwaki, and H. Kayaba et al., “Peroxisome proliferator-activated receptor regulates eosinophil functions: a new therapeutic target for allergic airway inflammation,” International Archives of Allergy and Immunology, vol. 134, supplement 1, pp. 30–36, 2004.
- M. Hetzel, D. Walcher, M. Grüb, H. Bach, V. Hombach, and N. Marx, “Inhibition of MMP-9 expression by PPAR activators in human bronchial epithelial cells,” Thorax, vol. 58, no. 9, pp. 778–783, 2003.
- H. J. Patel, M. G. Belvisi, D. Bishop-Bailey, M. H. Yacoub, and J. A. Mitchell, “Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy,” Journal of Immunology, vol. 170, no. 5, pp. 2663–2669, 2003.
- R. Pawliczak, C. Han, X.-L. Huang, A. J. Demetris, J. H. Shelhamer, and T. Wu, “85-kDa cytosolic phospholipase mediates peroxisome proliferator-activated receptor activation in human lung epithelial cells,” Journal of Biological Chemistry, vol. 277, no. 36, pp. 33153–33163, 2002.
- G. R. Bernard, A. Artigas, and K. L. Brigham et al., “The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination,” American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 3, part 1, pp. 818–824, 1994.
- L. B. Ware and M. A. Matthay, “The acute respiratory distress syndrome,” New England Journal of Medicine, vol. 342, no. 18, pp. 1334–1349, 2000.
- Y. Sivan, C. Mor, S. Al-Jundi, and C. J. Newth, “Adult respiratory distress syndrome in severely neutropenic children,” Pediatric Pulmonology, vol. 8, no. 2, pp. 104–108, 1990.
- M. A. Matthay and J. P. Wiener-Kronish, “Intact epithelial barrier function is critical for the resolution of alveolar edema in humans,” American Review of Respiratory Disease, vol. 142, no. 6, pp. 1250–1257, 1990.
- J. I. Sznajder, “Strategies to increase alveolar epithelial fluid removal in the injured lung,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 5 part 1, pp. 1441–1442, 1999.
- W. M. Zapol, R. L. Trelstad, J. W. Coffey, I. Tsai, and R. A. Salvador, “Pulmonary fibrosis in severe acute respiratory failure,” American Review of Respiratory Disease, vol. 119, no. 4, pp. 547–554, 1979.
- J. F. Tomashefski, “Pulmonary pathology of the adult respiratory distress syndrome,” Clinics in Chest Medicine, vol. 11, no. 4, pp. 593–619, 1990.
- A. C. J. Windsor, C. J. Walsh, and P. G. Mullen et al., “Tumor necrosis factor- blockade prevents neutrophil CD18 receptor upregulation and attenuates acute lung injury in porcine sepsis without inhibition of neutrophil oxygen radical generation,” Journal of Clinical Investigation, vol. 91, no. 4, pp. 1459–1468, 1993.
- P. R. Colville-Nash, S. S. Qureshi, D. Willis, and D. A. Willoughby, “Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1,” Journal of Immunology, vol. 161, no. 2, pp. 978–984, 1998.
- G. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000.
- R. B. Clark, “The role of PPARs in inflammation and immunity,” Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388–400, 2002.
- A. E. Lovett-Racke, R. Z. Hussain, and S. Northrop et al., “Peroxisome proliferator-activated receptor agonists as therapy for autoimmune disease,” Journal of Immunology, vol. 172, no. 9, pp. 5790–5798, 2004.
- T. Genovese, E. Mazzon, and R. Di Paola et al., “Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma,” Experimental Neurology, vol. 194, no. 1, pp. 267–278, 2005.
- H. Okamoto, T. Iwamoto, S. Kotake, S. Momohara, H. Yamanaka, and N. Kamatani, “Inhibition of NK-B signaling by fenofibrate, a peroxisome proliferator-activated receptor- ligand, presents a therapeutic strategy for rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 23, no. 3, pp. 323–330, 2005.
- P. Delerive, K. De Bosscher, and S. Besnard et al., “Peroxisome proliferator-activated receptor negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-B and AP-1,” Journal of Biological Chemistry, vol. 274, no. 45, pp. 32048–32054, 1999.
- P. Delerive, P. Gervois, J.-C. Fruchart, and B. Staels, “Induction of IB expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor- activators,” Journal of Biological Chemistry, vol. 275, no. 47, pp. 36703–36707, 2000.
- E. Dyrøy, A. Yndestad, and T. Ueland et al., “Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor -dependent and -independent pathways,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 7, pp. 1364–1369, 2005.
- S. Cuzzocrea, E. Mazzon, and R. Di Paola et al., “The role of the peroxisome proliferator-activated receptor- (PPAR-) in the regulation of acute inflammation,” Journal of Leukocyte Biology, vol. 79, no. 5, pp. 999–1010, 2006.
- C. Delayre-Orthez, J. Becker, and I. Guenon et al., “PPAR downregulates airway inflammation induced by lipopolysaccharide in the mouse,” Respiratory Research, vol. 6, p. 91, 2005.
- T. Genovese, E. Mazzon, and R. Di Paola et al., “Role of peroxisome proliferator-activated receptor- in acute pancreatitis induced by cerulein,” Immunology, vol. 118, no. 4, pp. 559–570, 2006.
- P. Jiang, J.-C. Wang, Y.-M. Zhao, and G.-S. Qian, “Influence and mechanism of peroxisome proliferation activated receptor- expression induced by WY14643 in rat lung with acute lung injury,” Zhongguo Weizhongbing Jijiuyixue, vol. 18, no. 8, pp. 466–469, 2006.
- T. Genovese, E. Mazzon, and R. Di Paola et al., “Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor in the development of bleomycin-induced lung injury,” Shock, vol. 24, no. 6, pp. 547–555, 2005.
- S. Cuzzocrea, N. S. Wayman, and E. Mazzon et al., “The cyclopentenone prostaglandin 15-deoxy--prostaglandin attenuates the development of acute and chronic inflammation,” Molecular Pharmacology, vol. 61, no. 5, pp. 997–1007, 2002.
- S. Cuzzocrea, B. Pisano, and L. Dugo et al., “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-, reduces acute inflammation,” European Journal of Pharmacology, vol. 483, no. 1, pp. 79–93, 2004.
- M. Abdelrahman, M. Collin, and C. Thiemermann, “The peroxisome proliferator-activated receptor- ligand 15-deoxy prostaglandin reduces the organ injury in hemorrhagic shock,” Shock, vol. 22, no. 6, pp. 555–561, 2004.
- S. Cuzzocrea, B. Pisano, and L. Dugo et al., “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-, reduces the development of nonseptic shock induced by zymosan in mice,” Critical Care Medicine, vol. 32, no. 2, pp. 457–466, 2004.
- D. Liu, B. X. Zeng, and Y. Shang, “Decreased expression of peroxisome proliferator-activated receptor in endotoxin-induced acute lung injury,” Physiological Research, vol. 55, no. 3, pp. 291–299, 2006.
- M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.
- S. Ohtsuka, M. Kakihana, H. Watanabe, T. Enomoto, R. Ajisaka, and Y. Sugishita, “Alterations in left ventricular wall stress and coronary circulation in patients with isolated systolic hypertension,” Journal of Hypertension, vol. 14, no. 11, pp. 1349–1355, 1996.
- R. M. Strieter, R. Wiggins, and S. H. Phan et al., “Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells,” Biochemical and Biophysical Research Communications, vol. 162, no. 2, pp. 694–700, 1989.
- H. Ishii, M. Ishibashi, M. Takayama, T. Nishida, and M. Yoshida, “The role of cytokine-induced neutrophil chemoattractant-1 in neutrophil-mediated remote lung injury after intestinal ischaemia/reperfusion in rats,” Respirology, vol. 5, no. 4, pp. 325–331, 2000.
- P. L. Khimenko, G. J. Bagby, J. Fuseler, and A. E. Taylor, “Tumor necrosis factor- in ischemia and reperfusion injury in rat lungs,” Journal of Applied Physiology, vol. 85, no. 6, pp. 2005–2011, 1998.
- M. Okada, S. F. Yan, and D. J. Pinsky, “Peroxisome proliferator-activated receptor- (PPAR-) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets,” The FASEB Journal, vol. 16, no. 14, pp. 1861–1868, 2002.
- T. J. Standiford, V. C. Keshamouni, and R. C. Reddy, “Peroxisome proliferator-activated receptor- as a regulator of lung inflammation and repair,” Proceedings of the American Thoracic Society, vol. 2, no. 3, pp. 226–231, 2005.
- K.-I. Inoue, H. Takano, and R. Yanagisawa et al., “Effect of 15-deoxy--prostaglandin on acute lung injury induced by lipopolysaccharide in mice,” European Journal of Pharmacology, vol. 481, no. 2-3, pp. 261–269, 2003.
- H. A. Burgess, L. E. Daugherty, and T. H. Thatcher et al., “PPAR agonists inhibit TGF- induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis,” Lung Cellular and Molecular Physiology, vol. 288, no. 6, pp. L1146–L1153, 2005.
- T. Genovese, S. Cuzzocrea, and R. Di Paola et al., “Effect of rosiglitazone and 15-deoxy--prostaglandin on bleomycin-induced lung injury,” European Respiratory Journal, vol. 25, no. 2, pp. 225–234, 2005.
- M. Ando, Y. Murakami, and F. Kojima et al., “Retrovirally introduced prostaglandin synthase suppresses lung injury induced by bleomycin,” American Journal of Respiratory Cell and Molecular Biology, vol. 28, no. 5, pp. 582–591, 2003.
Copyright © 2007 Rosanna Di Paola and Salvatore Cuzzocrea. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.